Barcelona, Spain – September 10, 2026 – The 2026 European Respiratory Society (ERS) International Congress, held from September 5th to 9th in Barcelona, Spain, has concluded, leaving a palpable sense of momentum and renewed optimism in the pulmonary fibrosis (PF) landscape. For a disease that has historically seen limited therapeutic advancements, the conference served as a pivotal platform, showcasing cutting-edge research and offering promising glimpses into the future of patient care. Discussions ranged from the potential impact of new therapeutic agents on treatment paradigms and payer decisions to significant clinical updates and intriguing developments in related conditions like chronic cough.
n
This year’s ERS congress underscored a significant shift, moving beyond the established treatments of nintedanib and pirfenidone, which revolutionized the field in 2014. Experts and analysts alike noted a dynamic acceleration in research and development, with multiple promising avenues emerging simultaneously. This resurgence of innovation has been likened by some to the transformative period of 2014, when two groundbreaking therapies were approved, marking a significant turning point for patients living with idiopathic pulmonary fibrosis (IPF) and other progressive forms of the disease.
n
In an in-depth discussion on the GlobalData Healthcare podcast, Manasi Vaidya, editor at GlobalData Insights, engaged with Connor Daniels, a seasoned healthcare analyst at GlobalData Healthcare, who provided firsthand insights from his attendance at the ERS 2026 conference. Daniels offered a comprehensive dissection of the scientific discourse, focusing on the emerging treatments for IPF and progressive pulmonary fibrosis (PPF), as well as key clinical milestones unveiled at this premier global gathering.
n
Jascayd and Inhaled Treprostinil: A Double Act of Promise
n
A significant focal point of ERS 2026 was the emerging research surrounding Boehringer Ingelheim’s Jascayd (nerandomilast). The novel compound has garnered considerable attention for its potential to alter the treatment algorithm for pulmonary fibrosis. Early findings presented at the congress suggest that Jascayd could not only offer clinical benefits but also potentially influence critical decisions made by healthcare payers regarding reimbursement and broader clinical adoption. The implications of these findings are far-reaching, hinting at a potential expansion of therapeutic options for patients who may not fully respond to or tolerate existing treatments.
n
Adding to the burgeoning wave of positive news, United Therapeutics also presented compelling late-breaking data on the efficacy of inhaled treprostinil in patients with IPF. This development further reinforces the growing momentum in the PF space, demonstrating that innovation is not confined to a single molecule or company. The positive results with inhaled treprostinil offer another promising avenue for managing this complex and often debilitating condition, potentially providing a much-needed alternative or adjunctive therapy.
n
Daniels eloquently captured the current sentiment within the pulmonary fibrosis community, drawing a parallel to the often-unpredictable nature of public transportation. "Advances in the pulmonary fibrosis space are akin to London buses," he remarked. "You can wait for what feels like an eternity for one significant development, and then suddenly, two arrive at once. This is precisely the feeling we experienced at ERS 2026, mirroring the transformative period of 2014 when Boehringer Ingelheim’s Ofev (nintedanib) and Roche’s Esbriet (pirfenidone) received their landmark approvals." This analogy underscores the rapid and impactful progress being made, signaling a departure from the slow trickle of innovation that characterized previous decades.
n
A Look Back: The Transformative Era of 2014
n
The year 2014 marked a watershed moment in the management of pulmonary fibrosis. The approvals of nintedanib and pirfenidone represented the first major therapeutic breakthroughs for IPF in decades. Prior to these approvals, treatment options were largely supportive, focusing on symptom management and slowing disease progression without offering significant disease-modifying benefits.
n
- n
- Nintedanib (Ofev): Developed by Boehringer Ingelheim, nintedanib is a tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis. Its approval was based on pivotal Phase III trials demonstrating a significant reduction in the rate of lung function decline in patients with IPF. This marked a paradigm shift, offering a targeted approach to slowing the irreversible scarring of lung tissue.
- Pirfenidone (Esbriet): Developed by Roche, pirfenidone is an anti-fibrotic and anti-inflammatory agent. Clinical trials showed that pirfenidone could also slow the rate of lung function decline in IPF patients. Its approval provided another crucial tool for physicians and patients, expanding the therapeutic armamentarium against this devastating disease.
n
n
n
The introduction of these two drugs fundamentally changed the outlook for IPF patients, offering tangible hope and improved prognoses. The subsequent years saw ongoing research to further understand their mechanisms, optimize their use, and identify patient populations who might benefit most. However, despite these advancements, significant unmet needs remained, driving the search for new and improved therapies.
n
ERS 2026: Unpacking the Latest Clinical Updates
n
The scientific sessions at ERS 2026 were replete with data that will undoubtedly shape clinical practice and future research agendas. Beyond the headline-grabbing announcements, a deeper dive into the presented studies reveals a nuanced understanding of disease mechanisms and the potential for novel therapeutic interventions.
n
Boehringer Ingelheim’s Jascayd (nerandomilast): Beyond the Hype
n
While the specific details of the clinical trial results for Jascayd were not fully elaborated in the initial report, the fact that they were a significant talking point at ERS 2026 speaks volumes. Nerandomilast, as a phosphodiesterase 4 (PDE4) inhibitor, targets inflammatory pathways implicated in fibrotic lung diseases. The anticipation surrounding its potential impact on reimbursement and clinical use suggests that the data presented demonstrated a compelling efficacy and safety profile, potentially offering a distinct advantage or a complementary role to existing therapies. Payers often look for clear evidence of improved clinical outcomes, reduced healthcare utilization, or enhanced patient quality of life when making formulary decisions. If Jascayd’s data meets these benchmarks, it could pave the way for broader access and integration into standard treatment protocols.
n
United Therapeutics’ Inhaled Treprostinil: Expanding the Horizon
n
The positive data from United Therapeutics with inhaled treprostinil in IPF is also a significant development. Treprostinil is a prostacyclin analogue that has been used for the treatment of pulmonary arterial hypertension (PAH). Its application in IPF suggests a potential role in addressing both the fibrotic and vascular components that can contribute to disease progression and symptoms in PF. The delivery method – inhaled – is also noteworthy, as it allows for targeted delivery to the lungs, potentially maximizing efficacy while minimizing systemic side effects. This could be particularly beneficial for patients who experience systemic adverse events with oral or intravenous medications.
n
Supporting Data and Emerging Mechanisms
n
While the article doesn’t delve into the specific statistical significance or detailed patient demographics of the presented studies, the mention of "emerging research" and "latest positive data" implies that the findings were robust enough to warrant discussion at a major international congress. Future reports will likely focus on:
n
- n
- Efficacy Endpoints: Such as the rate of lung function decline (e.g., Forced Vital Capacity – FVC), exacerbation rates, exercise capacity (e.g., 6-minute walk distance), and survival.
- Safety and Tolerability Profiles: Crucial for long-term patient management and adherence. Comparisons with existing therapies in terms of adverse event rates and severity will be vital.
- Biomarker Identification: Research presented at ERS often includes efforts to identify biomarkers that can predict disease progression, treatment response, or stratify patients for clinical trials.
- Mechanism of Action Insights: Deeper understanding of how these new agents interact with the complex cellular and molecular pathways driving pulmonary fibrosis.
n
n
n
n
n
Beyond Pulmonary Fibrosis: Signals in Chronic Cough
n
Intriguingly, Connor Daniels also highlighted "interesting signals from clinical trials in patients with chronic cough." This observation is significant because chronic cough is a debilitating symptom experienced by many patients with PF and other interstitial lung diseases. However, the management of chronic cough has been notoriously challenging, with a high rate of clinical trial failures in recent years.
The mention of "high-profile failures" points to the difficulties in identifying effective treatments for this complex symptom. The fact that ERS 2026 presented "interesting signals" suggests that new approaches or compounds are showing potential, perhaps by targeting specific underlying mechanisms of cough hypersensitivity or inflammation. This could have a direct impact on the quality of life for PF patients, alleviating a persistent and often distressing symptom that can significantly impair daily functioning and sleep.
Official Responses and Future Outlook
While the article does not include direct quotes from company representatives or regulatory bodies, the implications of the ERS 2026 presentations are clear.
- Boehringer Ingelheim and United Therapeutics: The positive data presented by these companies will likely fuel further development, regulatory submissions, and market access efforts. For Jascayd, the focus will be on demonstrating clear clinical value to secure favorable reimbursement. For United Therapeutics, the data will support the ongoing evaluation of inhaled treprostinil as a viable treatment option for IPF.
- Payers and Healthcare Providers: The emergence of new therapeutic options will necessitate a careful evaluation of their cost-effectiveness, clinical utility, and integration into existing treatment guidelines. Healthcare providers will be keen to understand the comparative efficacy and safety profiles of these new agents to make informed treatment decisions for their patients.
- Patient Advocacy Groups: These organizations will be instrumental in advocating for access to new and effective treatments, ensuring that patients benefit from the advancements discussed at ERS 2026.
The 2026 European Respiratory Society Congress has undoubtedly set a new trajectory for pulmonary fibrosis research and patient care. The convergence of promising research on Jascayd and inhaled treprostinil, coupled with potential breakthroughs in chronic cough management, signals a period of accelerated progress. The analogy of "two buses arriving at once" is a fitting descriptor for the current state of the field, offering a much-needed wave of innovation and renewed hope for individuals living with these challenging respiratory conditions. As these developments move through the pipeline, the coming years are poised to bring significant advancements, transforming the lives of countless patients.
